Pharmacotherapeutic Decisions In Menopausal Women With Cardiovascular Risk-Reference-Cited by-同舟云学术

Pharmacotherapeutic Decisions In Menopausal Women With Cardiovascular Risk

Published:2007-04-01 Issue:2 Volume:2 Page:197-210
ISSN:1746-0875
Container-title:Future Lipidology
language:en
Short-container-title:Future Lipidology

Author:

Dayspring Thomas¹,Pokrywka Gregory²

Affiliation:

1. North Jersey Institute of Menopausal Lipidology, 516 Hamburg Turnpike, Wayne; NJ 07470, USA Tex.: , Fax.: ,

2. Clinical Assistant Professor of Medicine North Jersey Institute of Menopausal Lipidology, 516 Hamburg Turnpike, Wayne; NJ 07470, USA Tex.: , Fax.: ,

Publisher

Informa UK Limited

Subject

Biochemistry

Link

https://www.tandfonline.com/doi/pdf/10.2217/17460875.2.2.197

Reference120 articles.

1. American Heart Association. 2006 Heart and stroke statistical update. Circulation 113, 85–151 (2006).

2. The writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288, 321–333 (2002).

3. Manson, JE, Hsia J, Johnson KC et al.: Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349, 523–534 (2003).

4. The writing group for the Women’s Health Initiative Investigators. Effects of Conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291, 1701–1712 (2004).

5. Hsia J, Langer RD, Manson JE et al.: Conjugated equine estrogens and coronary heart disease. The Women’s Health Initiative. Arch. Intern. Med. 166, 357–365 (2006).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Significance of Hormone Routes of Administration;Hormone Therapy;2013

2. Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: Counterpoint;American Journal of Obstetrics and Gynecology;2008-01